Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.